EGFR and central nervous system cancer: RAS/MAPK activation in glioma has been shown to result both from constitutive activation of receptor tyrosine kinases EGFR, PDGFRA, and c-MET as well by an inactivating mutation of NF1, a suppressor of RAS GTPase activity.